Generally, CD19/CD22 CAR T cell infusions alone appear to be a viable treatment option for adult patients with r/r Burkitt lymphoma without enough HSCs, but the clinical efficacy was relatively limited. This evidence concerns the gene CD22 and Burkitt lymphoma.